1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Human Plasma-derived Hyperimmune Product Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Human Plasma-derived Hyperimmune Product by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Human Plasma-derived Hyperimmune Product by Country/Region, 2018, 2022 & 2029
2.2 Human Plasma-derived Hyperimmune Product Segment by Type
2.2.1 Hepatitis B Immunoglobulins
2.2.2 Rabies Immunoglobulins
2.2.3 Tetanus Immunoglobulins
2.2.4 Rho(D) Immunoglobulins
2.2.5 Other
2.3 Human Plasma-derived Hyperimmune Product Sales by Type
2.3.1 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Type (2018-2023)
2.3.2 Global Human Plasma-derived Hyperimmune Product Revenue and Market Share by Type (2018-2023)
2.3.3 Global Human Plasma-derived Hyperimmune Product Sale Price by Type (2018-2023)
2.4 Human Plasma-derived Hyperimmune Product Segment by Application
2.4.1 Government Institution
2.4.2 Private Sector
2.4.3 Others
2.5 Human Plasma-derived Hyperimmune Product Sales by Application
2.5.1 Global Human Plasma-derived Hyperimmune Product Sale Market Share by Application (2018-2023)
2.5.2 Global Human Plasma-derived Hyperimmune Product Revenue and Market Share by Application (2018-2023)
2.5.3 Global Human Plasma-derived Hyperimmune Product Sale Price by Application (2018-2023)
3 Global Human Plasma-derived Hyperimmune Product by Company
3.1 Global Human Plasma-derived Hyperimmune Product Breakdown Data by Company
3.1.1 Global Human Plasma-derived Hyperimmune Product Annual Sales by Company (2018-2023)
3.1.2 Global Human Plasma-derived Hyperimmune Product Sales Market Share by Company (2018-2023)
3.2 Global Human Plasma-derived Hyperimmune Product Annual Revenue by Company (2018-2023)
3.2.1 Global Human Plasma-derived Hyperimmune Product Revenue by Company (2018-2023)
3.2.2 Global Human Plasma-derived Hyperimmune Product Revenue Market Share by Company (2018-2023)
3.3 Global Human Plasma-derived Hyperimmune Product Sale Price by Company
3.4 Key Manufacturers Human Plasma-derived Hyperimmune Product Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Human Plasma-derived Hyperimmune Product Product Location Distribution
3.4.2 Players Human Plasma-derived Hyperimmune Product Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Human Plasma-derived Hyperimmune Product by Geographic Region
4.1 World Historic Human Plasma-derived Hyperimmune Product Market Size by Geographic Region (2018-2023)
4.1.1 Global Human Plasma-derived Hyperimmune Product Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Human Plasma-derived Hyperimmune Product Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Human Plasma-derived Hyperimmune Product Market Size by Country/Region (2018-2023)
4.2.1 Global Human Plasma-derived Hyperimmune Product Annual Sales by Country/Region (2018-2023)
4.2.2 Global Human Plasma-derived Hyperimmune Product Annual Revenue by Country/Region (2018-2023)
4.3 Americas Human Plasma-derived Hyperimmune Product Sales Growth
4.4 APAC Human Plasma-derived Hyperimmune Product Sales Growth
4.5 Europe Human Plasma-derived Hyperimmune Product Sales Growth
4.6 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales Growth
5 Americas
5.1 Americas Human Plasma-derived Hyperimmune Product Sales by Country
5.1.1 Americas Human Plasma-derived Hyperimmune Product Sales by Country (2018-2023)
5.1.2 Americas Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2023)
5.2 Americas Human Plasma-derived Hyperimmune Product Sales by Type
5.3 Americas Human Plasma-derived Hyperimmune Product Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Human Plasma-derived Hyperimmune Product Sales by Region
6.1.1 APAC Human Plasma-derived Hyperimmune Product Sales by Region (2018-2023)
6.1.2 APAC Human Plasma-derived Hyperimmune Product Revenue by Region (2018-2023)
6.2 APAC Human Plasma-derived Hyperimmune Product Sales by Type
6.3 APAC Human Plasma-derived Hyperimmune Product Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Human Plasma-derived Hyperimmune Product by Country
7.1.1 Europe Human Plasma-derived Hyperimmune Product Sales by Country (2018-2023)
7.1.2 Europe Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2023)
7.2 Europe Human Plasma-derived Hyperimmune Product Sales by Type
7.3 Europe Human Plasma-derived Hyperimmune Product Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Human Plasma-derived Hyperimmune Product by Country
8.1.1 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales by Country (2018-2023)
8.1.2 Middle East & Africa Human Plasma-derived Hyperimmune Product Revenue by Country (2018-2023)
8.2 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales by Type
8.3 Middle East & Africa Human Plasma-derived Hyperimmune Product Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Human Plasma-derived Hyperimmune Product
10.3 Manufacturing Process Analysis of Human Plasma-derived Hyperimmune Product
10.4 Industry Chain Structure of Human Plasma-derived Hyperimmune Product
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Human Plasma-derived Hyperimmune Product Distributors
11.3 Human Plasma-derived Hyperimmune Product Customer
12 World Forecast Review for Human Plasma-derived Hyperimmune Product by Geographic Region
12.1 Global Human Plasma-derived Hyperimmune Product Market Size Forecast by Region
12.1.1 Global Human Plasma-derived Hyperimmune Product Forecast by Region (2024-2029)
12.1.2 Global Human Plasma-derived Hyperimmune Product Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Human Plasma-derived Hyperimmune Product Forecast by Type
12.7 Global Human Plasma-derived Hyperimmune Product Forecast by Application
13 Key Players Analysis
13.1 CSL Behring
13.1.1 CSL Behring Company Information
13.1.2 CSL Behring Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.1.3 CSL Behring Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 CSL Behring Main Business Overview
13.1.5 CSL Behring Latest Developments
13.2 Grifols
13.2.1 Grifols Company Information
13.2.2 Grifols Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.2.3 Grifols Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Grifols Main Business Overview
13.2.5 Grifols Latest Developments
13.3 Biotest
13.3.1 Biotest Company Information
13.3.2 Biotest Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.3.3 Biotest Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Biotest Main Business Overview
13.3.5 Biotest Latest Developments
13.4 Kedrion
13.4.1 Kedrion Company Information
13.4.2 Kedrion Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.4.3 Kedrion Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Kedrion Main Business Overview
13.4.5 Kedrion Latest Developments
13.5 CBPO
13.5.1 CBPO Company Information
13.5.2 CBPO Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.5.3 CBPO Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 CBPO Main Business Overview
13.5.5 CBPO Latest Developments
13.6 Emergent (Cangene)
13.6.1 Emergent (Cangene) Company Information
13.6.2 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.6.3 Emergent (Cangene) Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Emergent (Cangene) Main Business Overview
13.6.5 Emergent (Cangene) Latest Developments
13.7 Kamada
13.7.1 Kamada Company Information
13.7.2 Kamada Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.7.3 Kamada Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Kamada Main Business Overview
13.7.5 Kamada Latest Developments
13.8 CNBG
13.8.1 CNBG Company Information
13.8.2 CNBG Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.8.3 CNBG Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 CNBG Main Business Overview
13.8.5 CNBG Latest Developments
13.9 Hualan Bio
13.9.1 Hualan Bio Company Information
13.9.2 Hualan Bio Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.9.3 Hualan Bio Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Hualan Bio Main Business Overview
13.9.5 Hualan Bio Latest Developments
13.10 Shanghai RAAS
13.10.1 Shanghai RAAS Company Information
13.10.2 Shanghai RAAS Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.10.3 Shanghai RAAS Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Shanghai RAAS Main Business Overview
13.10.5 Shanghai RAAS Latest Developments
13.11 Sichuan Yuanda Shuyang
13.11.1 Sichuan Yuanda Shuyang Company Information
13.11.2 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.11.3 Sichuan Yuanda Shuyang Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Sichuan Yuanda Shuyang Main Business Overview
13.11.5 Sichuan Yuanda Shuyang Latest Developments
13.12 ADMA Biologics
13.12.1 ADMA Biologics Company Information
13.12.2 ADMA Biologics Human Plasma-derived Hyperimmune Product Product Portfolios and Specifications
13.12.3 ADMA Biologics Human Plasma-derived Hyperimmune Product Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 ADMA Biologics Main Business Overview
13.12.5 ADMA Biologics Latest Developments
14 Research Findings and Conclusion
| ※参考情報 ヒト血漿由来高度免疫製品とは、主にヒトの血漿から抽出された免疫グロブリンや特定の抗体を含む製品のことを指します。これらの製品は、免疫系を強化するために使用され、特定の病原体に対する抗体が豊富であることから「高度免疫製品」と呼ばれています。 まず、ヒト血漿由来高度免疫製品の定義について触れます。この製品は、特定の病気への曝露を受けたドナーから採取された血漿を原料としており、通常は一定の危険のある病原体に対して高い濃度の抗体を含んでいます。このような抗体は、特定の感染症予防や治療に利用されます。一般的には、特定の感染症（例えば、ウイルス性肝炎やインフルエンザなど）に対する免疫が強化されたドナーの血漿を使用します。 次に、ヒト血漿由来高度免疫製品の特徴について考えてみましょう。まず第一に、これらの製品は通常、比較的少数のドナーの血液から製造されるため、特定の感染症に対する高い抗体価を持っていることが期待されます。第二に、抽出された免疫成分は、他の血液製剤に比べて特異的な病原体に対して高い選択性を持ちます。これにより、特定の感染症に対する免疫を提供することが可能となります。 ヒト血漿由来高度免疫製品の種類には、主に免疫グロブリン（Ig）製剤が含まれています。これらはIgG、IgA、IgM等の異なるクラスの免疫グロブリンを含むことができ、それぞれが異なる特性を持ちます。Expeditedの抗体製品は、特定の感染症に対するもので、抗体価が高く、迅速に効果を発揮する特徴があります。例えば、COVAXXやNabi Biopharmaceuticalsの開発した製品では、特定のウイルスに対する抗体を濃縮して使用しています。 用途については、よく知られているのは、感染症の予防や治療に用いられることです。特に急性感染症、免疫不全状態における補助療法、または特定の病気のアウトブレイク時における緊急対応としての使用が一般的です。さらに、高度免疫製品は、医療機関において患者の免疫を強化するために使用されることが多く、重篤な感染症による合併症の予防に効果的であるとされています。また、特定の病気に感染した患者への早期投与が、病状の悪化を防ぐ助けとなることがあります。 さらに、ヒト血漿由来高度免疫製品に関連する技術も多く存在します。特にプロセスの面では、血漿分離技術が重要です。これにより、血液中の必要な成分を効率的に抽出し、濃縮することが可能となります。また、製品製造における安全性が重視されるため、ウイルス不活化や除去技術が支持されています。これには、熱処理や溶媒/界面活性剤（S/D）処理などの方法が用いられ、病原体の影響を最小限に抑えるための措置が講じられています。 また、最近では遺伝子工学技術を用いた新たな開発が進んでおり、特定の抗体の研究や新しい免疫製品の開発が行われています。これにより、従来の製品では対応が難しかった病原体に対する免疫製品の製造が期待されています。 ヒト血漿由来高度免疫製品は、特に感染症の流行時において、その迅速かつ強力な効果が求められる製品です。これまでの研究成果を基に、さらなる技術革新が進むことで、今後もより多様な感染症に対する対応が可能になることが期待されます。目的適応に応じた製品開発や、信頼性と安全性の向上に向けた努力が、今後の医療において重要な役割を果たすでしょう。 |
*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
